Literature DB >> 24449066

Evolution of Charcot-Marie-Tooth disease type 1A duplication: a 2-year clinico-electrophysiological and lower-limb muscle MRI longitudinal study.

Ana L Pelayo-Negro1, Elena Gallardo, Antonio García, Pascual Sánchez-Juan, Jon Infante, José Berciano.   

Abstract

The objective of this study was to analyze Charcot-Marie-Tooth disease type 1A (CMT1A) evolution. We conducted a 2-year longitudinal study in 14 CMT1A patients and 14 age- and sex-matched controls. In the patients, we performed neurological examination with hand-held dynamometry, electrophysiology, and lower-limb muscle MRI, both at baseline and 2 years later, while controls were examined at baseline only. Patients' ages ranged from 12 to 51 years. Outstanding manifestations on initial evaluation included pes cavus, areflexia, lower-limb weakness, and foot hypopallesthesia. In evaluating muscle power, good correlation was observed between manual testing and dynamometry. Compared to controls, Lunge, 10-Meter-Walking, and 9-Hole-Peg tests were impaired. Their CMT neuropathy score and functional disability scale showed that patients exhibited mild phenotype and at most slight walking difficulty. Electrophysiology revealed marked nerve conduction slowing and variable compound muscle action potential amplitude reduction. On lower-limb muscle MRI, there was distally accentuated fatty infiltration accompanied by edema in calf muscles. All these clinico-electrophysiological and imaging findings remained almost unaltered during monitoring. Using multivariate analysis, no significant predictors of progression associated to the disease were obtained. We conclude that in the 2-year period of study, CMT1A patients showed mild progression with good concordance between clinico-electrophysiological and imaging findings.

Entities:  

Mesh:

Year:  2014        PMID: 24449066     DOI: 10.1007/s00415-014-7248-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  37 in total

Review 1.  MR imaging in nonneoplastic muscle disorders of the lower extremity.

Authors:  Joshua M Farber; Kenneth A Buckwalter
Journal:  Radiol Clin North Am       Date:  2002-09       Impact factor: 2.303

Review 2.  New insights into the pathophysiology of pes cavus in Charcot-Marie-Tooth disease type 1A duplication.

Authors:  José Berciano; Elena Gallardo; Antonio García; Ana L Pelayo-Negro; Jon Infante; Onofre Combarros
Journal:  J Neurol       Date:  2011-05-18       Impact factor: 4.849

3.  Tripod pinch strength and thumb opposition are the major determinants of manual dexterity in Charcot-Marie-Tooth disease type 1A.

Authors:  Annemieke J Videler; Anita Beelen; Ivo N van Schaik; Camiel Verhamme; Leonard H van den Berg; Marianne de Visser; Frans Nollet
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-06-18       Impact factor: 10.154

4.  Reliability and validity of the CMT neuropathy score as a measure of disability.

Authors:  M E Shy; J Blake; K Krajewski; D R Fuerst; M Laura; A F Hahn; J Li; R A Lewis; M Reilly
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

5.  Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A.

Authors:  K M Krajewski; R A Lewis; D R Fuerst; C Turansky; S R Hinderer; J Garbern; J Kamholz; M E Shy
Journal:  Brain       Date:  2000-07       Impact factor: 13.501

6.  Anterior tibialis CMAP amplitude correlations with impairment in CMT1A.

Authors:  Kelsey Komyathy; Stephanie Neal; Shawna Feely; Lindsey J Miller; Richard A Lewis; George Trigge; Carly E Siskind; Michael E Shy; Sindhu Ramchandren
Journal:  Muscle Nerve       Date:  2013-03-03       Impact factor: 3.217

7.  Different clinical and magnetic resonance imaging features between Charcot-Marie-Tooth disease type 1A and 2A.

Authors:  K W Chung; B C Suh; M E Shy; S Y Cho; J H Yoo; S W Park; H Moon; K D Park; K G Choi; S Kim; S B Kim; D S Shim; S M Kim; I N Sunwoo; B O Choi
Journal:  Neuromuscul Disord       Date:  2008-07-07       Impact factor: 4.296

8.  Neuropathy progression in Charcot-Marie-Tooth disease type 1A.

Authors:  M E Shy; L Chen; E R Swan; R Taube; K M Krajewski; D Herrmann; R A Lewis; M P McDermott
Journal:  Neurology       Date:  2008-01-29       Impact factor: 9.910

9.  The clinical features of hereditary motor and sensory neuropathy types I and II.

Authors:  A E Harding; P K Thomas
Journal:  Brain       Date:  1980-06       Impact factor: 13.501

10.  Postural instability in Charcot-Marie-Tooth type 1A patients is strongly associated with reduced somatosensation.

Authors:  Marleen H van der Linden; Saskia C van der Linden; Henk T Hendricks; Baziel G M van Engelen; Alexander C H Geurts
Journal:  Gait Posture       Date:  2010-03-11       Impact factor: 2.840

View more
  5 in total

1.  Functional MRI and laser-evoked potentials evaluation in Charcot-Marie-Tooth syndrome.

Authors:  Simona De Salvo; Lilla Bonanno; Roberto Giorgianni; Nunzio Muscarà; Francesco Freni; Fabrizia Caminiti; Demetrio Milardi; Placido Bramanti; Silvia Marino
Journal:  Neurol Sci       Date:  2018-04-11       Impact factor: 3.307

Review 2.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

3.  Nine-hole Peg Test and Ten-meter Walk Test for Evaluating Functional Loss in Chinese Charcot-Marie-Tooth Disease.

Authors:  Hui-Xia Niu; Rui-Hao Wang; Hong-Liang Xu; Bo Song; Jing Yang; Chang-He Shi; Yu-Sheng Li; Bing-Qian Zhang; Shao-Ping Wang; Quan Yong; Yuan-Yuan Wang; Yu-Ming Xu
Journal:  Chin Med J (Engl)       Date:  2017-08-05       Impact factor: 2.628

4.  New insights into intrinsic foot muscle morphology and composition using ultra-high-field (7-Tesla) magnetic resonance imaging.

Authors:  Melinda M Franettovich Smith; James M Elliott; Aiman Al-Najjar; Kenneth A Weber; Mark A Hoggarth; Bill Vicenzino; Paul W Hodges; Natalie J Collins
Journal:  BMC Musculoskelet Disord       Date:  2021-01-21       Impact factor: 2.362

5.  MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study.

Authors:  Jasper M Morrow; Christopher D J Sinclair; Arne Fischmann; Pedro M Machado; Mary M Reilly; Tarek A Yousry; John S Thornton; Michael G Hanna
Journal:  Lancet Neurol       Date:  2015-11-06       Impact factor: 44.182

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.